Primary Site >> Pancreatic Cancer
Gene >> SLC28A1
|
|
|
|
|
|
|---|---|---|---|---|---|
|
Ref: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. PMID: 14581375 |
Ref: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. PMID: 20028759 Ref: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. PMID: 20665488 |
Ref: CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. PMID: 21343396 |
Ref: Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. PMID: 22622284 Ref: Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. PMID: 22838950 |
Ref: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. PMID: 22580602 Ref: Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner. PMID: 23722537 Ref: The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. PMID: 23934321 |
Ref: Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. PMID: 25837929 Ref: The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. PMID: 25890497 |